Therefore, cotreatment with PARP inhibitor and TMZ (or procarbazine) appears to be a reasonable strategy in the therapy of promoter-unmethylated gliomas with a bad prognosis (Figure 5). Here, PARP1 is linked to central nervous system cancer.